Wednesday, July 2, 2025 7/2/2025

GPR171 As a Novel Target to Treat Neuropathic Pain

Award Number: R03TR003667
ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2021
PERIOD OF PERFORMANCE END DATE: 04/30/2024

Group Awards By:

View Award Description

GPR171 As a Novel Target to Treat Neuropathic Pain - PROJECT SUMMARY Millions of chronic pain patients lack adequate therapeutics to treat their pain. Orphan G-protein coupled receptors could be a new avenue to investigate for the treatment of pain and a variety of other health concerns. One interesting candidate is GPR171 that recently was found to be the receptor of the highly abundant neuropeptide, BigLEN. The purpose of this proposed research is to investigate the neural circuitry of this system, BigLEN-GPR171, and its ability to alleviate chronic pain. Our preliminary data show that a GPR171 agonist has antinociceptive properties in chronic pain. In addition, neuropathic pain downregulates GPR171 expression within a key brain region, periaqueductal gray, that is involved in pain modulation. Our hypothesis is that GPR171 within the periaqueductal gray regulates neuropathic pain. To test this hypothesis, we will use molecular and behavioral pharmacology to investigate a GPR171 agonist on chemotherapy-induced neuropathic pain and decipher which brain areas are mediating these responses. Aim 1 will determine the effectiveness of long-term treatment with a GPR171 agonist on treating chronic neuropathic pain. Alterations in GPR171 expression and signaling within the descending pain circuit following chronic pain will be investigated in Aim 2a by using molecular techniques. Aim 2b will use viral knockdown and local administration of GPR171 compounds to determine the role of the periaqueductal gray in relieving neuropathic pain. Overall, this innovative research has important pain therapeutic implications, as it will enhance our understanding of the physiological functions of this novel neuropeptide system.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$2,960 )
2024	2021	UTAH STATE UNIVERSITY	1000 OLD MAIN HL	LOGAN	UT	84322	CACHE	USA	Trans-NIH Research Support	000	1	7/22/2024	NEW	-$2,960
														Subtotal = -$2,960

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2021	UTAH STATE UNIVERSITY	1000 OLD MAIN HILL	LOGAN	UT	84322	CACHE	USA	Trans-NIH Research Support	000	1	4/6/2023	NEW	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $143,561 )
2021	2021	UTAH STATE UNIVERSITY	1000 OLD MAIN HILL	LOGAN	UT	84322	CACHE	USA	Trans-NIH Research Support	000	1	4/26/2021	NEW	$143,561
														Subtotal = $143,561

Grand Total All Awards = $140,601

Top

All Categories

About

Search

Reports

Data Submission

Award Information

GPR171 As a Novel Target to Treat Neuropathic Pain

Award Number: R03TR003667

ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2021

PERIOD OF PERFORMANCE END DATE: 04/30/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer